Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARIMIDEX | ANI Pharmaceuticals | N-020541 RX | 1995-12-27 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
anastrozole | ANDA | 2025-04-03 |
arimidex | New Drug Application | 2024-12-23 |
lactulose | ANDA | 2012-05-01 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
Code | Description |
---|---|
S0170 | Anastrozole, oral, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Drug common name | Anastrozole |
INN | anastrozole |
Description | Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile. |
Classification | Small molecule |
Drug class | aromatase inhibitors (imidazole/triazole derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1 |
PDB | — |
CAS-ID | 120511-73-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1399 |
ChEBI ID | 2704 |
PubChem CID | 2187 |
DrugBank | DB01217 |
UNII ID | 2Z07MYW1AZ (ChemIDplus, GSRS) |